+ cotransport system, which is distinct from PepT1, and that the fluorescein/H + cotransport system is involved in the uptake of nateglinide. The aim of this study was to characterize the functional properties of the intestinal nateglinide transporter. In the first part of this study, we demonstrated that the ceftibuten/H + cotransport system is identical to the fluorescein/H + cotransport system. We succeeded in purification of the nateglinide transporter from brush-border membranes of the rat small intestine using p-aminobenzoic acid (PABA)-affinity chromatography.
We then investigated the functional properties of the nateglinide transporter using proteoliposomes prepared from the PABA-affinity chromatography elute. We demonstrated that nateglinide, ceftibuten and fluorescein are transported by the same transporter in the intestine.
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(-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine (nateglinide)
is administered to patients with type 2 diabetes (noninsulin-dependent diabetes mellitus). Although nateglinide is a non-sulfonylurea anti-diabetic agent, it stimulates insulin secretion via the same mechanism as that by which insulin secretion is stimulated by sulfonylureas. It is known that sulfonylurea therapy has several disadvantages, such as excess hypoglycemia between meals, due to the long duration of action of these agents. Nateglinide, on the other hand, can compensate for impaired insulin secretion to prevent postprandial hyperglycemia without causing prolonged hypoglycemia because it quickly reaches the maximal serum concentration and is eliminated quite rapidly after oral administration [1] [2] [3] . These characteristics of nateglinide are expected to be useful in the treatment of type 2 diabetes.
The unique feature of nateglinide is its rapid intestinal absorption. However, physicochemical characteristics of nateglinide are incompatible with rapid absorption by passive diffusion. Thus, nateglinide is thought to be absorbed via a specific transport system(s) in the intestine. Peptide transporter 1 (PEPT1/SLC15A1) has been shown to mediate the efficient absorption of a wide variety of oral peptide-like drugs in the small intestine [4, 5] . In addition to PEPT1, at least five isoforms of MCT (MCT1, MCT2, MCT4, MCT5 and MCT8) are present in the small intestine, but only MCT1-MCT4 have been characterized in terms of their substrates and inhibitor kinetics [6, 7] . Nateglinide possesses a peptide-type bond and a carboxyl group in its structure, though it is not transported by Pept1 or MCT1 [8, 9] . Recently, we have -3-shown that nateglinide transport occurs via the ceftibuten/H + cotransport system, which is distinct from PepT1, and that the fluorescein/H + cotransport system is involved in the uptake of nateglinide [10] [11] [12] . Since kinetic analysis of nateglinide uptake by an Eadie-Hofstee plot gave a single straight line, it is possible that the ceftibuten/H + cotransport system is identical to the fluorescein/H + cotransport system.
However, these transport systems have not yet been elucidated at the molecular level.
It is thought that the physical isolation and the elucidation of functional properties of transport proteins are indispensable for further understanding of the transport mechanisms.
The present study was carried out to characterize the functional properties of the intestinal nateglinide transporter. We succeeded in purification of the nateglinide transporter from brush-border membranes of the rat small intestine using affinity chromatography. We then investigated the functional properties of the nateglinide transporter using prepared proteoliposomes.
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Materials and methods
Chemicals. Nateglinide and ceftibuten were kindly donated by Yamanouchi (Tokyo, Japan) and Sankyo (Tokyo, Japan), respectively. Fluorescein was purchased from Nacalai Tesque (Kyoto, Japan). Salicylic acid was purchased from Wako Pure Chemical (Osaka, Japan). All other reagents were of the highest grade available and used without further purification.
Animals. Male Wistar rats, aged 6 to 7 weeks (300-350 g in weight), were obtained from NRC Haruna (Gunma, Japan). The housing conditions were described previously [13] . The experimental protocols were reviewed and approved by the Hokkaido University Animal Care Committee in accordance with the "Guide for the Care and Use of Laboratory Animals".
Preparation of brush-border membrane vesicles. Brush-border membrane vesicles were prepared from the rat intestine by the calcium precipitation method with some modification as described previously [14] . All steps were performed on ice or at Protein characterization and determination. The purity of various active fractions was determined by SDS-polyacrylamide gel electrophoresis (SDS-PAGE).
Prior to SDS-PAGE, protein was precipitated by the method of Wessel and Flugge [18] . The dried protein precipitates were dissolved in 10 µl of a loading buffer containing 100 mM Tris/HCl (pH 6. until use. The coupling ratio was found to be approx. 96% as estimated from the amount of PABA remaining in the washing solutions after HPLC analysis.
Application onto a PABA-affinity column. All steps were performed at 4°C.
The 250 mM phosphate-eluted fraction from the hydroxyapatite column was applied to a PABA column equilibrated with buffer B (0.1% Triton X-100, 10% glycerol, 20
mM Tris/HCl, pH 7.4). After washing the PABA-affinity column with four column volumes of buffer B, the bound proteins were eluted from the affinity column by 50-1000 µM NaCl in buffer B. After pooling the eluates, the eluates were concentrated until 200 µl and desalted. Desalting was performed on a 2-ml Sephadex G50 medium (Amersham Pharmacia Biotech) column equilibrated in buffer A.
-10-Analytical procedures. Nateglinide and ceftibuten were determined using an HPLC system equipped with a JASCO 880-PU pump 870-UV UV/VIS detector. The column was a Hitachi ODS Gel #3053 (4 mm i.d. x 250 mm). In the assay for nateglinide, a mobile phase containing 50 mM H 3 PO 4 (pH 2.5) : acetonitrile (55:45, v/v) was used. Column temperature and flow rate were 55°C and 0.7 ml/min, respectively. The wavelength for detection of nateglinide was 210 nm. In the assay for ceftibuten, a mobile phase containing acetonitrile/0.05M citric acid buffer with pH adjusted to 2.5 by NaOH (1:9) was used. Column temperature and flow rate were 25°C and 0.7 ml/min, respectively. The wavelength for detection of ceftibuten was 262 nm. In the assay for PABA, a mobile phase containing 50 mM NaH 2 PO 4 , 0.5 mM tetrabutylammonium hydrogensulfate : methanol (82:18, v/v) was used. Column temperature and flow rate were 55°C and 0.5 ml/min, respectively. The wavelength for detection of PABA was 254 nm. Peptide bands were subjected to Edman degradation procedures, and the first ten amino-terminal amino acids were elucidated.
Student's t-test was used for statistical analysis, and a value of P < 0.05 was considered significant. Nonlinear regression analysis and least-squares fitting for the Eadie-Hofstee plot of substrate uptake were performed by using Origin ® (version 6.1J).
Results

Ceftibuten/H + and fluorescein/H + cotransporters
In order to clarify whether the nateglinide/ceftibuten cotransport system is identical to the nateglinide/fluorescein cotransport system, the inhibitory effects of ceftibuten and fluorescein on the uptake of nateglinide were investigated. As shown in Fig. 1 , ceftibuten significantly reduced the uptake of nateglinide. This inhibitory effect was saturable at a concentration of more than 5 mM. Moreover, the inhibitory effect of 0.5 mM fluorescein and that of 10 mM ceftibuten were almost the same. 
Hydroxyapatite chromatography of intestinal brush-border membrane proteins
The first purification step consisted of chromatography on hydroxyapatite. Fig.4 shows the nateglinide transport activity of the proteoliposomes reconstituted from phosphate-eluted fractions. The proteoliposomes reconstituted from the 250 mM -12-phosphate-eluted fraction showed a high uptake activity. The 250 mM phosphate-eluted fraction was used for inhibition studies and further purification.
Since we have reported that benzoic acid and salicylic acid significantly inhibited the uptake of nateglinide by Caco-2 cells [19] , cis-inhibition studies were performed using benzoic acid and salicylic acid. As shown in Table 1 , both of them significantly reduced the uptake of nateglinide. Moreover, ceftibuten and fluorescein significantly inhibited the nateglinide uptake. However, analysis of each fraction by SDS-PAGE revealed that many different protein bands were still present (data not shown).
Dixon plot analysis of nateglinide uptake in the presence of benzoic acid
The next purification step consisted of affinity chromatography. In order to determine the immobilized substrate, we investigated the inhibitory effect of benzoic acid on the uptake of nateglinide by rat intestinal brush-border membrane vesicles.
Results of Dixon plot analysis of nateglinide uptake in the presence of benzoic acid and an inwardly directed H + gradient are shown in Fig. 5 . Benzoic acid was demonstrated to inhibit the uptake of nateglinide competitively. The regression line obtained from the replot of slopes of the Dixon plot almost coincided with the origin (Fig. 5, inset) , indicating that benzoic acid transport is mediated by a common H + /cotransport system with nateglinide. The apparent Ki value calculated from Dixon plots for benzoic acid was 3.70 mM.
PABA-immobilized affinity chromatography of the 250 mM phosphate-eluted fraction
Since benzoic acid and nateglinide are thought to share the same transport system at intestinal brush-border membranes, we selected p-aminobenzoic acid (PABA), a derivative of benzoic acid, as a model substrate. Fig. 6A shows the nateglinide transport activity of the proteoliposomes reconstituted from NaCl-eluted fractions. The proteoliposomes reconstituted from the 500 mM NaCl-eluted fraction showed a high level of uptake activity. Analysis of each fraction by SDS-PAGE revealed the presence of proteins with apparent molecular masses of 66, 57 and 34 kDa (Fig. 6B ). There was a correlation between the 57-kDa protein and the transport activity. The first ten amino-terminal amino acids of the 57-kDa protein were elucidated. The amino terminal sequence of the 57-kDa protein was determined to be GGLTVSDMEG. The identified amino acid sequence was not identical to those of previously reported transport proteins. However, some transporters had similar homology to nateglinide/H + cotransporter. The other major 66-kDa and 34-kDa proteins represented sucrase-isomaltase and rat maleic acid dehydrogenase, respectively.
Properties of the purified nateglinide/H + cotransporter
Since the final yield of the purified nateglinide/H + cotransporter was very small, detailed kinetic studies were difficult to perform. cis-Inhibition and trans-stimulation studies were performed using salicylic acid. Salicylic acid -14-significantly reduced the uptake of nateglinide (Fig. 7A) . Furthermore, salicylic acid was able to induce an almost 2-fold trans-stimulation (Fig. 7B) . To determine whether nateglinide is taken up through the ceftibuten/fluorescein transporter, trans-stimulation experiments were performed using proteoliposomes preloaded with ceftibuten and fluorescein. As shown in Fig. 8 , by preloading with ceftibuten and fluorescein, the uptake of nateglinide was significantly enhanced.
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Discussion
Oral delivery is generally the most desirable means of drug administration, mainly because of patient acceptance, convenience in administration, and cost-effective manufacturing. However, there are several problems for the development of oral delivery systems for drugs [20] . One of the major problems is the poor permeability through the intestinal mucosa. The use of transporter function offers the possibility of delivering a drug to the target organ, avoiding distribution to other organs (thereby reducing the risk of toxic effects), controlling the elimination process, and improving oral bioavailability [21, 22] . Intestinal PEPT1 has been utilized to improve the intestinal absorption of poorly absorbed and pharmacologically active agents by chemically converting them to substrates for PEPT1 [5, 23] . In addition to PEPT1, intestinal MCT isoforms are possible targets for drug absorption [6, 7] .
Since nateglinide is absorbed rapidly form the intestine, it is likely to be absorbed via a specific transporter(s) [2, 3] . However, nateglinide is not transported by PEPT1 or MCT1 [8, 9] . We have recently shown that nateglinide is absorbed in the intestinal brush-border membrane via the ceftibuten/H + cotransport system, which is distinct from PepT1, and that the fluorescein/H + cotransport system is involved in the uptake of nateglinide [12] . In the present study, we purified intestinal nateglinide transporter and characterized the functional properties of this transporter.
In the first part of this study, we investigated whether the ceftibuten/H + -16-cotransport system is identical to the fluorescein/H + cotransport system [10, 11] . The inhibitory effect of the combined treatment on the uptake of nateglinide into rat brush-border membrane vesicles was not greater than that of ceftibuten or fluorescein alone. Moreover, fluorescein inhibited the uptake of ceftibuten competitively. The results suggest that the ceftibuten/H + cotransport system is identical to the fluorescein/H + cotransport system and that nateglinide is transported by this transport system.
Various membrane transport proteins have been purified using hydroxyapatite in the presence of detergents. Based on this purification method for membrane proteins, we developed a purification protocol for the new nateglinide transporter. By using hydroxyapatite chromatography, we succeeded in obtaining fractions enriched in transport activity. However, many different proteins were still present in the phosphate-eluted fraction of hydroxyapatite chromatography. Further purification was needed.
The next purification step consisted of affinity chromatography. Since the results from Dixon plot analysis suggest that benzoic acid and nateglinide share the same transport system at intestinal brush-border membranes, we selected PABA, a derivative of benzoic acid, as a model substrate. By using PABA-immobilized affinity chromatography, we succeeded in obtaining fractions enriched in transport activity.
SDS-PAGE analysis showed only one protein band with a molecular mass of approximately 57 kDa, correlating with the transport activity of nateglinide.
-17-Moreover, it is unlikely that the 66-kDa protein, sucrase-isomaltase, and 34-kDa protein, rat maleic acid dehydrogenase, are involved in the transport of nateglinide.
We then investigated the functional properties of the nateglinide transporter using proteoliposomes prepared from the PABA-affinity chromatography elute. Salicylic acid was found to have not only an inhibitory effect on the transport of nateglinide but also a trans-stimulation effect. These results indicate that we can evaluate the trans-stimulation effect using prepared proteoliposomes. It was found that both ceftibuten and fluorescein are able to induce trans-stimulation. These findings indicate that nateglinide, ceftibuten and fluorescein are transported by the same transporter in the intestine.
The absorption of drugs from the gastrointestinal tract is one of the important determinants for oral bioavailability. It is now widely recognized that drug transporters contribute to the absorption of administered drugs from the intestine and that drug targeting is an effective approach to increase the pharmaceutical activity of drugs. Utilization of PEPT1 has been considered to be a promising strategy for oral drug delivery [5, 23] . However, drug-drug interactions involving PEPT1 are likely to occur due to the broad substrate specificity of PEPT1. Transporter-mediated drug-drug interactions involving drugs that have a narrow therapeutic range may have serious adverse consequences. Substrate specificity of the nateglinide transport system is more similar to that of MCTs than that of Pept1 [12] . By utilizing the nateglinide transport system as the target for oral drug delivery, it will be possible to -18-avoid drug-drug interactions involving PEPT1. In addition to PEPT1, intestinal MCTs may represent a novel target for improving oral bioavailability [7] . Therefore, elucidation of the molecular structure, function and regulation of MCTs is important in drug delivery and design. In this study, we have shown that a dianionic compound, ceftibuten, inhibits the transport of monocarboxylic compounds, nateglinide and fluorescein. The results of this study provide important information for further studies aimed at elucidation of the substrate recognition mechanism of MCTs.
In summary, we have demonstrated that the ceftibuten/H + cotransport system is identical to the fluorescein/H + cotransport system and that nateglinide, ceftibuten and fluorescein are transported by the same transporter in the intestine. Incubation conditions were identical to those described in the legend to Fig. 7B . Each column represents the mean with S.D. of 3 determinations. *P< .05, **P < .01, significantly different from the control.
Legends for figures
-26- The uptake of nateglinide (50 µM) by proteoliposomes was determined in the presence or absence of inhibitors. Incubation conditions were identical to those described in the legend to Fig. 4 . Each value represents the mean with S.D. of 3 determinations. **P < .01, significantly different from the control.
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